Merz Forms Fully Focused Global Medical Aesthetics Business: Merz Aesthetics

• Merz Group reorganizes into three distinct customer-focused businesses
• Appoints Bob Rhatigan as global chief executive officer of Merz Aesthetics®

Merz, a global leader in the field of aesthetics and neurotoxins, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care. Under this structure, Merz Aesthetics will be the largest dedicated medical aesthetics business globally. The reorganization was announced as Merz reported the completion of another year of strong business performance across all regions, exceeding fiscal year 2018/19 revenue targets. Merz’s global revenue growth of 6.8 percent was driven in part by 17 percent year-over-year growth in the aesthetics business.

In this new structure, all functions and aspects of global Merz Aesthetics business will be solely focused on serving the needs of customers. Merz Aesthetics global management team will now be based in Raleigh, North Carolina, centering the business in the largest and one of the fastest growing aesthetics markets in the world. Merz will start operating in the new structure January 1, 2020.

As part of this reorganization, Bob Rhatigan has been appointed global chief executive officer of Merz Aesthetics, assuming responsibility for all aspects of the global aesthetics business. Rhatigan previously served as CEO of Merz Americas. He has driven both Xeomin® (incobotulinumtoxinA) and Ultherapy® to double-digit growth, making Xeomin the fastest growing neurotoxin in the U.S. medical aesthetics market, and more than doubled Merz’s flagship injectable filler, Radiesse, in Latin America.

“We are pleased to make this change from a position of strength as an organization and in support of our long-term sustainability strategy. This positions Merz Aesthetics as the world’s only global fully-focused, medical aesthetics business, committed first and foremost to customers,” said Philip Burchard, Chief Executive Officer of the Merz Group. “Bob’s focus on customers, vision to expand our R&D efforts and drive to position Merz as the leading global medical aesthetics business, have materially strengthened who we are as a company and I warmly welcome Bob to this new role.”

“I am honored to lead this exceptional organization of dedicated and talented people,” said Rhatigan, global CEO of Merz Aesthetics. “Through the creation of a specialized global medical aesthetics business, we will become even more relentlessly focused on meeting the needs of our customers worldwide and helping to facilitate their success.”

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Merz Worldwide

With approximately 3,000 employees and a direct presence in 28 countries, Merz is a global, family-owned aesthetics and neurotoxin company based in Frankfurt, Germany. Privately held for 110 years, the company is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In addition to its comprehensive portfolio of medical aesthetic products in the device, injectable and skincare categories, Merz also develops neurotoxin therapy to treat neurologically-induced movement disorders. In fiscal year 2016/17, Merz generated revenue of EUR 1,092.9 million.